S. Barnett

1.7k total citations
19 papers, 283 citations indexed

About

S. Barnett is a scholar working on Pediatrics, Perinatology and Child Health, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, S. Barnett has authored 19 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pediatrics, Perinatology and Child Health, 7 papers in Oncology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in S. Barnett's work include Childhood Cancer Survivors' Quality of Life (7 papers), Acute Lymphoblastic Leukemia research (7 papers) and Drug Transport and Resistance Mechanisms (4 papers). S. Barnett is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (7 papers), Acute Lymphoblastic Leukemia research (7 papers) and Drug Transport and Resistance Mechanisms (4 papers). S. Barnett collaborates with scholars based in United Kingdom, United States and Germany. S. Barnett's co-authors include Kayode Ogungbenro, Karelle Ménochet, Aleksandra Galetin, Hong Shen, W. Griffith Humphreys, Gareth J. Veal, Yurong Lai, Shaunna Beedie, Neil Vargesson and Cindy H. Chau and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

S. Barnett

17 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Barnett United Kingdom	8	151	111	82	76	34	19	283
Christopher Rowbottom United States	9	155 1.0×	61 0.5×	95 1.2×	45 0.6×	19 0.6×	9	346
Andrew P. Beelen United States	12	235 1.6×	67 0.6×	161 2.0×	49 0.6×	71 2.1×	35	553
Ilaria Badagnani United States	8	208 1.4×	107 1.0×	84 1.0×	60 0.8×	52 1.5×	13	377
Svetlana Markova United States	3	196 1.3×	94 0.8×	122 1.5×	98 1.3×	22 0.6×	6	416
Chie Ogawa Japan	11	181 1.2×	93 0.8×	161 2.0×	45 0.6×	15 0.4×	20	482
Y. Anne Pak United States	8	212 1.4×	91 0.8×	71 0.9×	107 1.4×	8 0.2×	9	355
Woo‐Young Kim South Korea	14	217 1.4×	88 0.8×	222 2.7×	105 1.4×	22 0.6×	24	534
George Cusatis United States	7	414 2.7×	100 0.9×	174 2.1×	86 1.1×	14 0.4×	8	516
EG Burchard United States	3	262 1.7×	123 1.1×	204 2.5×	71 0.9×	25 0.7×	6	498
Nathan D. Pfeifer United States	10	251 1.7×	113 1.0×	51 0.6×	141 1.9×	38 1.1×	14	409

Countries citing papers authored by S. Barnett

Since Specialization

Citations

This map shows the geographic impact of S. Barnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Barnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Barnett more than expected).

Fields of papers citing papers by S. Barnett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Barnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Barnett. The network helps show where S. Barnett may publish in the future.

Co-authorship network of co-authors of S. Barnett

This figure shows the co-authorship network connecting the top 25 collaborators of S. Barnett. A scholar is included among the top collaborators of S. Barnett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Barnett. S. Barnett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Vormoor, Britta, Joshua Savage, Geoff Shenton, et al.. (2026). Responses can be achieved with a combination of the MEK inhibitor selumetinib and dexamethasone in patients with relapsed/refractory RAS-pathway mutated acute lymphoblastic leukemia: Results of a parallel cohort, dose-finding and expansion phase I/II trial. University of Birmingham Research Portal (University of Birmingham). 7. 100489–100489.

Duncan, Catriona, et al.. (2024). Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom. British Journal of Cancer. 131(3). 491–497. 1 indexed citations

Barnett, S., et al.. (2024). Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. British Journal of Clinical Pharmacology. 91(4). 1064–1079. 3 indexed citations

Amant, Frédéric, Jos H. Beijnen, S. Barnett, et al.. (2023). Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk. CPT Pharmacometrics & Systems Pharmacology. 12(12). 1931–1944. 5 indexed citations

Barnett, S., et al.. (2023). Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report. Cancer Chemotherapy and Pharmacology. 92(4). 325–328.

Barnett, S., Guy Makin, Deborah A. Tweddle, Caroline Osborne, & Gareth J. Veal. (2023). Generation of evidence-based carboplatin dosing guidelines for neonates and infants. British Journal of Cancer. 129(11). 1773–1779. 4 indexed citations

Barnett, S., Victoria Holden, Quentin Campbell‐Hewson, & Gareth J. Veal. (2022). Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations. Frontiers in Oncology. 11. 815040–815040. 4 indexed citations

Vos‐Kerkhof, Evelien de, Catherine F. Enters-Weijnen, Mirjam E. van de Velde, et al.. (2022). A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children. Pharmaceutical Research. 39(10). 2487–2495. 6 indexed citations

Barnett, S., Rebecca Rees, Olga Slater, et al.. (2022). Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series. Pediatric Blood & Cancer. 69(7). e29722–e29722. 3 indexed citations

10.

Bashir, Saira, David Burke, Elizabeth Ruth Plummer, et al.. (2022). A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3103–3103. 4 indexed citations

11.

Barnett, S., Guy Makin, Deborah A. Tweddle, et al.. (2021). Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. European Journal of Cancer. 164. 127–136. 22 indexed citations

12.

Barnett, S., Arief Lalmohamed, Deborah A. Tweddle, et al.. (2021). Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance. European Journal of Cancer. 164. 137–154. 10 indexed citations

13.

Barnett, S., Julie Errington, Julieann Sludden, et al.. (2021). Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population. Pharmaceuticals. 14(3). 272–272. 19 indexed citations

14.

Barnett, S., et al.. (2020). Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. British Journal of Clinical Pharmacology. 87(2). 256–262. 7 indexed citations

15.

Takita, Hiroyuki, S. Barnett, Yueping Zhang, et al.. (2020). PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability. CPT Pharmacometrics & Systems Pharmacology. 10(2). 137–147. 27 indexed citations

16.

Barnett, S., Kayode Ogungbenro, Karelle Ménochet, et al.. (2018). Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I. Journal of Pharmacology and Experimental Therapeutics. 368(1). 125–135. 43 indexed citations

17.

Barnett, S., Kayode Ogungbenro, Karelle Ménochet, et al.. (2017). Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clinical Pharmacology & Therapeutics. 104(3). 564–574. 65 indexed citations

18.

Beedie, Shaunna, S. Barnett, Cindy H. Chau, et al.. (2016). In vivoscreening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget. 7(22). 33237–33245. 33 indexed citations

19.

Beedie, Shaunna, Cody J. Peer, Erin R. Gardner, et al.. (2015). Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Molecular Cancer Therapeutics. 14(10). 2228–2237. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact